Frankfurt
09.02.26 | 08:23
0,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LIDDS Aktie jetzt für 0€ handeln | |||||
| 23.02. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.02.2026 | 819 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 23.02.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.02.2026.ISIN NameCA4987222060 KLONDIKE... ► Artikel lesen | |
| 13.02. | LIDDS AB: LIDDS is declared bankrupt - delisting from First North | 438 | GlobeNewswire (Europe) | On 13 February 2026, the Gothenburg District Court decided to file LIDDS AB (publ) in liquidation ("the Company") for bankruptcy.
Mona Jonasson, Layer at law firm NORDIA Göteborg KB, has been appointed... ► Artikel lesen | |
| 13.02. | LIDDS AB - Removal from trading on Nasdaq First North Growth Market | 347 | GlobeNewswire | Today, February 13, 2026, LIDDS AB was declared bankrupt by the Gothenburg District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to... ► Artikel lesen | |
| 09.02. | LIDDS AB: The liquidator intends to file for bankruptcy as the conditions for completing the liquidation are lacking | 269 | GlobeNewswire (Europe) | Gothenburg, 09/02/2026 - LIDDS AB (publ) ("LIDDS" or the "Company"), listed on Nasdaq First North Growth Market, announces today that the liquidator appointed by the Swedish Companies Registration Office... ► Artikel lesen | |
| 09.02. | XFRA 5LD: AUSSETZUNG/SUSPENSION | 361 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLIDDS AB 5LD SE0001958612... ► Artikel lesen | |
| 09.02. | Suspension of Trading in LIDDS AB at FNSE | 329 | GlobeNewswire | 2026-02-09T15:59:18Z
Suspension
At Trading Venue FNSE
Due to Other
Ongoing:
True
Comments: Nasdaq Stockholm has, to the extent applicable, also decided to
suspend the trading in all other instruments... ► Artikel lesen | |
| 28.01. | LIDDS AB: Announcement from extraordinary general meeting, as well as second control meeting, in LIDDS AB (publ) held on 28 January 2026 | 141 | GlobeNewswire (Europe) | LIDDS AB (publ) (the "Company") has held an extraordinary general meeting, as well as second control meeting, on 28 January 2026. A summary of the resolutions made at the general meeting follows below.... ► Artikel lesen | |
| 09.01. | The observation status for LIDDS AB is updated | 292 | GlobeNewswire | On April 2, 2025, the shares in LIDDS AB (the "Company") were given observation status with reference to the Company's decision to cease further development of the project areas Nanodotax, Nanoimod... ► Artikel lesen | |
| 09.01. | LIDDS AB: LIDDS AB (publ) proposes that the general meeting, as well as the second control meeting, resolve on voluntary liquidation and the delisting of the company's shares | 346 | GlobeNewswire (Europe) | GOTHENBURG, SWEDEN - The Board of Directors of LIDDS AB (publ) ("LIDDS" or the "Company") has today resolved to propose that an extraordinary general meeting, which will also serve as the second control... ► Artikel lesen | |
| 18.12.25 | LIDDS AB: Announcement from extraordinary general meeting in LIDDS AB (publ) held on 18 December 2025 | 326 | GlobeNewswire (Europe) | LIDDS AB (publ) (the "Company") has held an extraordinary general meeting on 18 December 2025. A summary of the resolutions made at the general meeting follows below. All resolutions have been made... ► Artikel lesen | |
| 11.12.25 | The observation status for LIDDS AB is updated | 297 | GlobeNewswire | On April 2, 2025, the shares in LIDDS AB (the "Company") were given observation status with reference to the Company's decision to cease further development of the project areas Nanodotax, Nanoimod... ► Artikel lesen | |
| 10.12.25 | LIDDS AB: LIDDS AB (publ) has decided to terminate the process regarding the reverse acquisition of Proport Invest AB (publ) | 204 | GlobeNewswire (Europe) | The Board of Directors of LIDDS AB (publ) ("LIDDS" or the "Company") has, after completing due diligence, decided to discontinue the ongoing process for the reverse acquisition of Proport Invest AB... ► Artikel lesen | |
| 28.11.25 | The observation status for LIDDS AB is updated | 262 | GlobeNewswire | On April 2, 2025, the shares in LIDDS AB (the "Company") were given observation status with reference to the Company's decision to cease further development of the project areas Nanodotax, Nanoimod... ► Artikel lesen | |
| 27.11.25 | LIDDS AB: LIDDS AB (publ) has entered into an agreement for a reverse takeover of Proport Invest AB (publ) | 271 | GlobeNewswire (Europe) | LIDDS AB (publ) ("LIDDS" or the "Company") announces that the Company has entered into an agreement for a reverse takeover of Proport Invest AB (publ) ("Proport") regarding all shares in Proport (the... ► Artikel lesen | |
| 20.11.25 | LIDDS AB: LIDDS AB (publ) Interim Report January - September 2025 | 179 | GlobeNewswire (Europe) | July - September 2025Net sales amounted to 0 (0) KSEKThe operating result for the period was -876 (-1,061) KSEKThe net result was -891 (-877) KSEK corresponding to earningsper share of -0.01 (-0.01)... ► Artikel lesen | |
| 13.11.25 | LIDDS AB: The board of directors of LIDDS AB intends to propose a reduction of the company's share capital for loss coverage | 206 | GlobeNewswire (Europe) | GOTHENBURG, SWEDEN - The board of directors of LIDDS AB (publ) ("LIDDS" or the "Company") intends to propose that an extraordinary general meeting of the Company resolve on a reduction of the Company's... ► Artikel lesen | |
| 28.08.25 | LIDDS AB: LIDDS AB (publ) Interim Report January - June 2025 | 245 | GlobeNewswire (Europe) | April - June 2025Net sales amounted to 0 (0) KSEKThe operating result for the period was -836 (-2 391) KSEKThe net result was -733 (-2 398) KSEK corresponding to earnings per share of -0,01 (-0.02)... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 50,12 | -1,14 % | Märkte am Morgen: Bayer, Deutsche Bank, SAP, Delivery Hero, Easyjet, ASML | Der DAX hat in der vergangenen Woche abgeliefert. Ein Plus von 4,5 Prozent bedeutet die beste Handelswoche seit April 2025. Vor allem an den letzten Tagen blies der DAX zur Rekordjagd, stellte eine... ► Artikel lesen | |
| MERCK KGAA | 139,35 | -0,18 % | Aktien Frankfurt Ausblick: Dax kaum bewegt nach Rekord | FRANKFURT (dpa-AFX) - Nach seinem Rekordlauf in der vergangenen Woche dürfte der Dax am Montag seine Gewinne halten. Stützend wirken teils freundliche Aktienmärkte in Asien. Dort sorge die Aussicht... ► Artikel lesen | |
| NOVO NORDISK | 43,280 | -0,22 % | Novo Nordisk: Kursziel rauf | Stück für Stück arbeitet sich die Aktie von Novo Nordisk aus dem Tal der Tränen. Zum Start in die neue Handelswoche verbucht das Papier des dänischen Biopharma-Konzerns an der Heimatbörse in Kopenhagen... ► Artikel lesen | |
| PMGC | 1,110 | -0,89 % | PMGC Holdings Inc.: NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression | Independent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,540 | -0,15 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 77,84 | 0,00 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| KARDIGAN | 24,550 | -0,34 % | TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline | ||
| PFIZER | 21,210 | +0,07 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Pfizer von 30 auf 28 US-Dollar gesenkt und die Einstufung auf "Neutral" belassen. Seine Schätzungen für die Quartalszahlen am... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 36,720 | +0,30 % | Eton Pharmaceuticals Aktie erreicht Rekordhoch von 38,6 USD | ||
| LB PHARMACEUTICALS | 32,950 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | ||
| ELI LILLY | 1.038,60 | -0,23 % | Megatrend Folger: Eli Lilly sprengt die Billionen-Marke | Eli Lilly marschiert weiter an der Spitze des globalen Gesundheitssektors. Die Aktie des US-Pharmagiganten kletterte am Dienstag auf ein neues Allzeithoch und lässt damit die Marke von einer Billion... ► Artikel lesen | |
| CHINA PHARMA HOLDINGS | 0,635 | 0,00 % | China Pharma: Keine Erklärung für ungewöhnliche Handelsaktivitäten | ||
| SCHOTT PHARMA | 20,750 | +3,75 % | DEUTSCHE BANK RESEARCH stuft Schott Pharma auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Schott Pharma von 16 auf 22 Euro angehoben und die Aktien von "Hold" auf "Buy" hochgestuft. Der Spezialist für Verpackung und... ► Artikel lesen | |
| VYNE THERAPEUTICS | 0,642 | +0,66 % | VYNE Therapeutics Inc.: VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience | NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has declared a special cash dividend (the "Cash... ► Artikel lesen | |
| ASTRAZENECA | 148,60 | -1,16 % | BERNSTEIN RESEARCH stuft ASTRAZENECA auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für Astrazeneca von 18600 auf 18900 Pence angehoben und die Einstufung auf "Outperform" belassen. Vielversprechende... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIDDS AB finden Sie auf Wallstreet Online.